Health Innovation Oxford and Thames Valley supported our early evidence generation and health economic evaluation — providing critical insights into Dora’s clinical effectiveness, safety, and cost-efficiency. This early-stage support enabled us to demonstrate value to the NHS and build a strong foundation for wider adoption.
Aisling Higham
